ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

Behavioral Therapies No Cure for Chronic Fatigue Syndrome (CFS)

  [ 51 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 12, 2001


JAMA study may be misleading

This article is reprinted with permission from The CFS Research Review Vol. 2, No. 4 Fall 2001.

A review article in the Sept. 19, 2001 issue of the Journal of the American Medical Association states what most familiar with the chronic fatigue syndrome (CFS) literature already know: studies of treatments in CFS involve small numbers of participants, use inconsistent outcome measures and yield mixed results.

The authors have summarized the results of two government-funded analyses (one from the U.S. and the other from the U.K.) of the treatment literature, including published and unpublished reports of pharmacologic, behavioral and other therapies. Nineteen databases were searched, identifying 350 studies conducted between 1986 and 2000. Of those, 44 research reports were included in the review, representing a total of 2,801 patients.

Reviewers selected studies of pharmacologic interventions including hydrocortisone, fludrocortisone and galanthamine and immunological therapies such as immunoglobulin, Ampligen and interferon. Trials of supplements such as essential fatty acids and magnesium were evaluated, as were studies of massage and osteopathy. Research on two behavioral interventions, graded exercise therapy (GET) and cognitive behavioral therapy (CBT), accounted for nine of the 44 studies.

Comparison of the studies proved challenging. There were considerable differences in study design (36 employed randomized controlled trials and eight used controlled trials), outcome measures (more than 38 different outcomes were assessed), duration of treatment (ranging from two to 52 weeks) and length of follow-up (ranging from two weeks to five years).

The authors highlighted CBT and GET as the most promising therapies, although they acknowledge that these studies also had the highest dropout rates of the 44. Five of the nine behavioral studies used the less-restrictive Oxford criteria to select patients, and all, by design, only included patients who were well enough to frequently travel to clinic.

Positive effects of other therapies received less attention. Of those studies with relatively high validity scores, independent trials of immunoglobulin, hydrocortisone, magnesium and essential fatty acids showed benefits.

The reviewers conclude that greater standardization of studies is needed. They suggest that a classification system for illness severity be developed, as well as guidelines for the duration of intervention and follow-up. Finally, the authors prioritize agreement upon outcome measures as a necessary step to improve the comparability of CFS studies.

The complete report of the U.S. evidence based review summarized in the JAMA article is due from the Agency for Healthcare Research and Quality in late November or early December. The U.K. literature analysis is available on the Internet at www.york.ac.uk/inst/crd/cfs.htm.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra EPA  - Fish Oil Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Coconut Oil - Healthy Gifts from the 'Tree of Life' Coconut Oil - Healthy Gifts from the 'Tree of Life'
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map